Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07840729
PHASE1

Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants

Sponsor: Shanghai JMT-Bio Inc.

View on ClinicalTrials.gov

Summary

Use these resources to provide understandable information about this study to patients, families, and health care providers:

Official title: Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is "Individual Patients." A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-10-20

Completion Date

2027-04-30

Last Updated

2026-09-25

Healthy Volunteers

No

Interventions

DRUG

JMT206 injection

JMT206 injection administered subcutaneously (SC) once a week

COMBINATION_PRODUCT

Semaglutide injection

Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.

DRUG

Placebo injection

Placebo administered subcutaneously (SC) once a week.

Locations (1)

Peking University People's Hospital

Beijing, China